Idarucizumab Reverses Dabigatran Anticoagulant Activity in Healthy Chinese Volunteers: A Pharmacokinetics, Pharmacodynamics, and Safety Study.
Zining WangXia ZhaoPengkang HeShuqing ChenJie JiangAkiko HaradaSteven BrooksYi Min CuiPublished in: Advances in therapy (2020)
ClinicalTrials.gov Identifier No. NCT03086356.